| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
25 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-63 |
| Cash Flow (TTM) (Millions $) |
-17 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Decibel Therapeutics Inc is a biotechnology company based in Boston, Massachusetts. The company focuses on developing therapies for the treatment of hearing and balance disorders. Their goal is to restore and preserve hearing by targeting the underlying causes of these conditions, such as sensorineural hearing loss.
Decibel Therapeutics utilizes a multidisciplinary approach that combines genetics, bioinformatics, and experimental biology to identify potential drug targets. They have a robust pipeline that includes both small molecule drugs and gene therapies. The company's approach is centered around understanding the biology of the inner ear and developing targeted interventions to improve hearing function.
Decibel Therapeutics collaborates with academic institutions, pharmaceutical companies, and patient advocacy groups to advance their research. Their ultimate objective is to positively impact the lives of individuals affected by hearing and balance disorders.
Company Address: 1325 Boylston Street Boston 2215 MA
Company Phone Number: 370-8701 Stock Exchange / Ticker: NASDAQ DBTX
|
%
1.88%